Novartis Investigational Compound LBH589 Met Primary Endpoint in Phase III Study

Novartis (NYSE: NVS ) today announced that results of a Phase III trial of the investigational compound LBH589 (panobinostat) in combination with bortezomib and dexamethasone, met the primary endpoint of significantly extending progression-free survival (PFS) in patients with relapsed or relapsed and refractory multiple myeloma when compared to bortezomib